| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 09/27/2011 | US8026279 Crystalline form of γ-aminobutyric acid analog |
| 09/27/2011 | US8026250 Compositions for delivering highly water soluble drugs |
| 09/27/2011 | US8026238 Topical antifungal composition |
| 09/27/2011 | US8026211 Methods and formulations for increasing intestinal function |
| 09/27/2011 | US8026209 Administering a diagnostic agent with a carrier conjugated to a targeting molecule that binds to a lipopolysaccharide-sensitive polypeptide, which is either up-regulated or down-regulated in ECs by exposure to LPS; delivery into the EC vascular barrier and/or across the EC vascular barrier |
| 09/27/2011 | US8025901 Bifunctional-modified hydrogels |
| 09/27/2011 | US8025900 Drug incorporated into carrier substrate of hyaluronic acid, amino acid or polyoxyalkylene glycol |
| 09/27/2011 | US8025899 Solid pharmaceutical dosage form |
| 09/27/2011 | US8025898 Enhanced drug delivery in transdermal systems |
| 09/27/2011 | US8025897 Ibuprofen composition |
| 09/27/2011 | US8025892 Cosmetic particulate gel carriers for topically applied active agents |
| 09/27/2011 | US8025658 Adhesive patch systems and methods |
| 09/27/2011 | US8025639 Methods of power injecting a fluid through an access port |
| 09/27/2011 | CA2532981C Ultra thin film transdermal/dermal or transmucosal/mucosal delivery system |
| 09/27/2011 | CA2530005C Use of buprenorphine for the treatment of drug dependence withdrawal in a pregnant woman |
| 09/27/2011 | CA2516733C Process for the production of particles |
| 09/27/2011 | CA2505742C Pharmaceutical compositions comprising a basic drug, a water soluble acid and a surfactant |
| 09/27/2011 | CA2503982C Sincalide formulations |
| 09/27/2011 | CA2495864C Aripiprazole complex formulation and method |
| 09/27/2011 | CA2490309C Anthelmintic oral homogeneous veterinary pastes |
| 09/27/2011 | CA2471284C Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same |
| 09/27/2011 | CA2463835C Dimeric compounds and their use as anti-viral agents |
| 09/27/2011 | CA2462337C Dimeric compounds and their use as anti-viral agents |
| 09/27/2011 | CA2445347C An orally administered agent and an orally administered agent/supporting substrate complex |
| 09/27/2011 | CA2436010C Water soluble powders and tablets |
| 09/27/2011 | CA2405811C Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
| 09/27/2011 | CA2385465C .alpha.-isomaltosylglucosaccharide-forming enzyme, process and uses of the same |
| 09/22/2011 | WO2011116286A2 Stable bortezomib formulations |
| 09/22/2011 | WO2011116219A1 Theranostic delivery systems with modified surfaces |
| 09/22/2011 | WO2011116188A1 Nylon-3 co-polymers and synthetic lung surfactant compositions containing same |
| 09/22/2011 | WO2011116154A2 Melt emulsification |
| 09/22/2011 | WO2011116139A2 Improved pharmaceutical compositions and methods of delivery |
| 09/22/2011 | WO2011116132A1 Heterogeneous implantable devices for drug delivery |
| 09/22/2011 | WO2011116115A1 Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing |
| 09/22/2011 | WO2011116072A1 Hybrid hydrogel scaffold compositions and methods of use |
| 09/22/2011 | WO2011116020A2 Ophthalmic formulations of cetirizine and methods of use |
| 09/22/2011 | WO2011115988A1 Compositions and methods of treating and preventing lung cancer |
| 09/22/2011 | WO2011115969A2 Process of manufacturing a lyophilized fast dissolving, muti-phasic dosage form |
| 09/22/2011 | WO2011115912A1 Synergistic preservative compositions |
| 09/22/2011 | WO2011115778A2 Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport |
| 09/22/2011 | WO2011115700A2 Emollient foams for treatment of seborrheic dermatitis |
| 09/22/2011 | WO2011115684A2 Lipid vesicle compositions and methods of use |
| 09/22/2011 | WO2011115599A2 Orally disintegrating tablet formulations of donepezil and process for preparing the same |
| 09/22/2011 | WO2011115489A2 Spray-pumpable composition suitable for topical skin application |
| 09/22/2011 | WO2011115342A1 Oral contrast medium for contrast of small intestine |
| 09/22/2011 | WO2011115272A1 Proteoglycan-containing microneedle array |
| 09/22/2011 | WO2011115264A1 Composition for transnasal administration and method for producing same |
| 09/22/2011 | WO2011115067A1 Method for improving dissolvability of anticoagulant |
| 09/22/2011 | WO2011114515A1 Manufacturing method for soft capsule using non-animal origin outer-skin, and soft capsule |
| 09/22/2011 | WO2011114225A1 Beta-propiolactone for inactivation of viruses in pharmaceutical pancreatic enzyme preparations |
| 09/22/2011 | WO2011114224A1 Gastro-resistant enzyme pharmaceutical compositions |
| 09/22/2011 | WO2011114002A1 Novel device |
| 09/22/2011 | WO2011113981A1 Water-soluble pharmaceutical composition comprising at least one therapeutically active substance having hydrophobic properties and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphingolipids and glycosphingolipids |
| 09/22/2011 | WO2011113855A2 Pharmaceutical composition for treatment of increased intraocular pressure |
| 09/22/2011 | WO2011113826A1 Novel topical corticosteroid formulation |
| 09/22/2011 | WO2011113616A1 A nanoparticle comprising a micelle formed by an amphiphilic block- copolymer and encapsulating a gadolinium complex |
| 09/22/2011 | WO2011113507A2 Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns |
| 09/22/2011 | WO2011113320A1 Pharmaceutical compositions comprising dronedarone |
| 09/22/2011 | WO2011113301A1 Self-emulsifying formulation of taxanes and preparation method thereof |
| 09/22/2011 | WO2011113300A1 Medicines for inhibiting toxicity or side effects caused by chemotherapeutic agents |
| 09/22/2011 | WO2011092720A3 Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts and process for their preparation |
| 09/22/2011 | WO2011078695A3 Acoustically sensitive drug delivery particles comprising low concentrations of phosphatidylethanolamine |
| 09/22/2011 | WO2011074931A3 Parenteral pharmaceutical formulation in suspension, having sustained release, in low and ultralow dosage, in hormonal therapy in the climacteric syndrome |
| 09/22/2011 | WO2011063178A3 Intravenous infusion of curcumin and a calcium channel blocker |
| 09/22/2011 | WO2011057235A3 Improved delivery of submicrometer and nonometer aerosols to the lungs using hygroscopic excipients or dual stream nasal delivery |
| 09/22/2011 | WO2011056545A3 Antimicrobial ionic liquids |
| 09/22/2011 | WO2011053792A3 Methods and compositions for sustained delivery of drugs |
| 09/22/2011 | WO2011053003A3 Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer |
| 09/22/2011 | WO2011050206A3 Compositions and methods for the treatment of sinonasal disorders |
| 09/22/2011 | WO2011050178A3 Targeted prdm gene or protein modulation therapeutic agents |
| 09/22/2011 | WO2011044516A3 Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease |
| 09/22/2011 | WO2011018474A8 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein |
| 09/22/2011 | WO2010129184A3 Magnetic particles for delivering therapeutic agent to a target location |
| 09/22/2011 | US20110230865 Sustained delivery of an active agent using an implantable system |
| 09/22/2011 | US20110230816 Gels for Transdermal Delivery |
| 09/22/2011 | US20110230510 Pharmaceutical formulations containing opioid agonist, opioid antagonist and gelling agent |
| 09/22/2011 | US20110230455 Aqueous-based pharmaceutical composition |
| 09/22/2011 | US20110230409 GLP-I Agonist And Cardiovascular Complications |
| 09/22/2011 | US20110229581 Releasable cationic lipids for nucleic acids delivery systems |
| 09/22/2011 | US20110229580 Compositions and methods for nano-in-micro particles |
| 09/22/2011 | US20110229579 Support Having Nanostructured Titanium Dioxide Film And Uses Thereof |
| 09/22/2011 | US20110229578 Modafinil oral lyophilizate |
| 09/22/2011 | US20110229577 Biologically active silicic acid |
| 09/22/2011 | US20110229576 Hollow silica nanospheres and methods of making same |
| 09/22/2011 | US20110229575 Deep immersion flotation therapy for burn victims |
| 09/22/2011 | US20110229574 Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
| 09/22/2011 | US20110229573 Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form |
| 09/22/2011 | US20110229572 Delivery of drug combinations |
| 09/22/2011 | US20110229571 Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker |
| 09/22/2011 | US20110229570 Orally rapidly disintegrating tablet and process for producing same |
| 09/22/2011 | US20110229569 Compositions exhibiting delayed transit through the gastrointestinal tract |
| 09/22/2011 | US20110229568 Michael systems as transglutaminase inhibitors |
| 09/22/2011 | US20110229567 Solid pharmaceutical composition |
| 09/22/2011 | US20110229566 Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof |
| 09/22/2011 | US20110229565 Drug Delivery Composition Comprising a Self-Assembled Gelator |
| 09/22/2011 | US20110229564 Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof |
| 09/22/2011 | US20110229563 Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity |
| 09/22/2011 | US20110229562 Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol |
| 09/22/2011 | US20110229561 Extended Release Pharmaceutical Composition Of Entacapone Or Salts Thereof |
| 09/22/2011 | US20110229560 Nlrc5 as a target for immune therapy |